Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.
Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.
Bolt Biotherapeutics (BOLT) will participate in two investor conferences, with its Stifel presentation scheduled for November 10, 2026.
Chief Strategy Officer Sheila Gujrathi will present and join a fireside chat at 10:40 a.m. ET, and attend the Jefferies Global Healthcare Conference in London on November 16–19. In October 2026, Bolt acquired Prana Therapies through a stock-for-stock reverse merger alongside $120 million in private placement financing. Accompanying warrants could provide up to an additional $60 million upon exercise. Bolt is now primarily focused on advancing Prana’s antibody pipeline, led by PRA-216, currently in Phase 2 development across multiple inflammatory diseases.
Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a stock-for-stock reverse merger and agreed to a concurrent $120 million private placement. The financing is expected to close October 26, 2026, with up to $60 million more available upon warrant exercise. Bolt expects the upfront proceeds to fund operations into 2028.
The acquired lead drug, PRA-216, is in Phase 2 development for asthma, chronic obstructive pulmonary disease and atopic dermatitis; a fourth trial in eosinophilic esophagitis is planned. Bolt expects patient data from all four trials beginning in the second quarter of 2027 and continuing through the fourth quarter. Existing Bolt holders will own approximately 6.9% on the stated fully diluted basis. Preferred-stock conversion requires Bolt shareholder approval. Prana co-founder Sheila Gujrathi became chief strategy officer and joined Bolt’s board.
Bolt Biotherapeutics (Nasdaq: BOLT) reported second quarter 2026 collaboration revenue of $5 thousand, down from $1.8 million a year earlier, with a net loss of $7.7 million and loss from operations of $8.4 million. R&D expenses fell to $5.1 million and G&A to $2.4 million, reflecting prior restructuring and lower activity.
Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027. Bolt’s lead ISAC candidate BDC-4182, targeting claudin 18.2 in gastric and gastroesophageal cancers, is in an ongoing Phase 1/2 trial with patients being treated in Cohort 4 at the 4.0 mg/kg dose; initial clinical data are expected with third quarter 2026 results. The rest of the pipeline, including BDC-3042 and preclinical ISAC programs, is currently on hold. Total assets were $40.3 million and stockholders’ equity $12.6 million at quarter end.
Bolt Biotherapeutics (Nasdaq:BOLT) reported Q1 2026 results and a business update. Collaboration revenue was $26,000 versus $1.2 million in Q1 2025. R&D expenses fell to $4.8 million and G&A to $2.8 million, reducing loss from operations to $7.6 million. Cash and investments totaled $23.9 million, expected to fund operations into 2027, including BDC-4182 Phase 1/2 dose escalation. Initial clinical data from BDC-4182 in gastric and gastroesophageal cancer are anticipated in 3Q 2026. Two additional ISAC programs targeting CEA and PD-L1 remain on hold pending BDC-4182 proof-of-concept.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q4 and full-year 2025 results and a development update. Key points: BDC-4182, a Boltbody ISAC targeting claudin 18.2, is in Phase 1 dose escalation with initial clinical data expected in 3Q 2026. Cash, cash equivalents, and marketable securities were $31.8 million as of December 31, 2025, which the company expects will fund milestones into 2027. Collaboration revenue totaled $2.5 million in Q4 2025; full-year R&D and G&A expenses declined versus 2024 following restructuring.
Bolt Biotherapeutics (Nasdaq: BOLT) announced management will participate in two March 2026 investor events: a company presentation at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:50 a.m. EST and one‑on‑one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026.
Bolt Biotherapeutics (Nasdaq: BOLT) reported third quarter 2025 results and a business update on Nov 12, 2025. Key clinical milestone: initial clinical data for BDC-4182 Phase 1 (gastric/gastroesophageal cancer) is expected in 3Q 2026. Cash, cash equivalents, and marketable securities totaled $38.8 million as of Sept 30, 2025, and are expected to fund milestones into 2027. Third-quarter collaboration revenue was $2.2M vs. $1.1M in 3Q24. R&D expense decreased to $6.5M from $13.8M year-over-year; G&A was $3.3M. Loss from operations improved to $7.7M from $16.4M. Company presented preclinical ISAC data at SITC and continues collaborations with Genmab and Toray.
Bolt Biotherapeutics (Nasdaq: BOLT) has announced updates regarding its Phase 1 dose escalation study of BDC-4182, their next-generation Boltbody™ ISAC targeting claudin 18.2 for cancer treatment. Due to strong immune responses observed at initial dose levels, the company is modifying the clinical trial protocol to implement step-up dosing, delaying initial clinical data release to Q3 2026.
To preserve capital, Bolt is implementing a 50% workforce reduction, which will extend their cash runway into 2027. The company will maintain focus on advancing BDC-4812 clinically and supporting their ISAC collaborations to enhance shareholder value.
Bolt Biotherapeutics (Nasdaq: BOLT) reported Q2 2025 financial results and business updates. The company's lead candidate, BDC-4182, a next-generation claudin 18.2 ISAC, has entered Phase 1 dose-escalation studies for gastric and gastroesophageal cancer. The company reported $48.5 million in cash as of June 30, 2025, expected to fund operations through mid-2026.
Q2 financial highlights include collaboration revenue of $1.8 million, reduced R&D expenses of $7.5 million (down from $15.4M in Q2 2024), and G&A expenses of $3.5 million (down from $4.9M). The company completed a 1:20 reverse stock split on June 6, 2025, regaining Nasdaq compliance. Bolt continues collaborations with Genmab and Toray while seeking a partner for BDC-3042, which showed partial response in lung cancer patients.